Analysis on Equilibrium Point of Expectation Propagation Using Information Geometry

Hideyuki Matsui,Toshiyuki TANAKA

DOI: https://doi.org/10.1007/978-3-642-03040-6_19

2009-07-30

Abstract:

What problem does this paper attempt to address?

The Associations Between Prenatal Cannabis Use Disorder and Neonatal Outcomes

Yuyan Shi,Bin Zhu,Di Liang

DOI: https://doi.org/10.1111/add.15467

2021-01-01

Addiction

Abstract:Background and Aims Cannabis use disorder (CUD) during pregnancy has increased dramatically in the United States (US). This study examined the associations between prenatal CUD and adverse neonatal outcomes and heterogeneities in the associations by mothers' tobacco use status and race/ethnicity. Design Population-based, retrospective cohort study. Setting California, USA. Participants A total of 4.83 million mothers who delivered a live singleton birth during 2001 to 2012 and their paired infants. Data were obtained from mother-infant linked hospital discharge records and birth and death certificates. Identified by ICD-9 codes recorded at delivery, 20 237 mothers had prenatal CUD. Measurements Neonatal outcomes included length of gestation, preterm birth, birth weight, admission into neonatal intensive care unit, hospitalization within 1 year of birth, and death within 1 year of birth. Propensity score matching was used to balance maternal, paternal, and infant characteristics in the comparisons between infants exposed and unexposed to prenatal CUD. Findings CUD increased from 2.8 to 6.9 per 1000 deliveries during 2001 to 2012. Multivariable regressions in matched samples estimated that prenatal CUD was associated with greater odds of being small for gestational age (OR = 1.13, 95% CI = 1.08, 1.18), preterm birth (OR = 1.06, 95% CI = 1.01, 1.12), low birth weight (OR = 1.13, 95% CI = 1.07, 1.20), and death within 1 year of birth (OR = 1.35, 95% CI = 1.12, 1.62). Compared with infants whose mothers were tobacco non-users, infants whose mothers were tobacco users had greater odds of preterm birth, low birth weight, hospitalization, and death in association with prenatal CUD. Compared with infants whose mothers were non-Hispanic White, infants whose mothers were Hispanic had greater odds of hospitalization and death and infants whose mothers were non-Hispanic Black had greater odds of being small for gestational age in association with prenatal CUD. Conclusion Prenatal cannabis use disorder appears to be associated with escalated odds of major adverse neonatal outcomes, with heterogeneities in the associations by mothers' tobacco use status and race/ethnicity.
Intentions to Use Cannabis Postpartum: A Qualitative Study of Pregnant Individuals Who Used Cannabis During Early Pregnancy

Kelly C. Young-Wolff,Andrea Green,Esti Iturralde,Andrea Altschuler,Monique B. Does,Melanie Jackson-Morris,Sara R. Adams,Deborah Ansley,Amy Conway,Nancy Goler,Kara Skelton,Tara R. Foti

DOI: https://doi.org/10.1089/jwh.2023.0066

2024-02-28

Journal of Women s Health

Abstract:Objective: To examine plans for postpartum cannabis use among pregnant individuals who used cannabis during early pregnancy. Materials and Methods: Eighteen virtual focus groups were conducted from November 17, 2021, to December 17, 2021, with 23 Black and 30 White pregnant adults in Kaiser Permanente Northern California, who self-reported prenatal cannabis use during early pregnancy. Focus groups were recorded, transcribed, and analyzed using thematic analysis. Results: The sample ( N = 53) had a mean age of 30.3 years (standard deviation = 5.2) at recruitment; 70% reported daily, 25% weekly, and 6% ≤ monthly cannabis use at entrance to prenatal care. Some participants viewed cannabis as critical for coping with postpartum mental and physical health challenges, while others questioned whether cannabis use would fit with their parental lifestyle, and some planned to abstain altogether. Most planned to use cannabis postpartum, but with lower frequency than before pregnancy, and in ways consistent with harm reduction ( e.g. , smoking outside to avoid secondhand or thirdhand smoke exposure). Many were motivated to abstain from cannabis while breastfeeding, and some desired more data on the safety of cannabis and breastfeeding, or intended to "pump and dump," believing it would reduce potential transfer of Δ 9 -tetrahydrocannabinol (THC) to their infant. Responses from Black and White participants were generally similar, but White participants were more likely to report plans to use cannabis while breastfeeding and to want information about cannabis and breastfeeding. Conclusions: Pregnant individuals with prenatal cannabis use had varied plans for cannabis use postpartum. Many were motivated to abstain or use cannabis less frequently than pre-pregnancy, especially during lactation.

medicine, general & internal,public, environmental & occupational health,obstetrics & gynecology,womens studies
Prenatal Cannabis Use and Offspring Attention Deficit Hyperactivity Disorder and Disruptive Behavior Disorders: A Retrospective Cohort Study

Kelly C Young-Wolff,Kevin Kong,Stacey E Alexeeff,Lisa A Croen,Nina Oberman,Harshal Kirane,Deborah Ansley,Meghan Davignon,Sara R Adams,Lyndsay A Avalos

DOI: https://doi.org/10.1097/DBP.0000000000001323

2024-10-15

Abstract:Objective: To examine whether maternal cannabis use during early pregnancy is associated with offspring attention deficit hyperactivity disorder (ADHD) and disruptive behavior disorders (DBD). Methods: We conducted a population-based retrospective birth cohort study of children (N = 141,570) born between 2011 and 2018 to pregnant individuals (N = 117,130) in Kaiser Permanente Northern California universally screened for any prenatal cannabis use at the entrance to prenatal care (at ∼8-10 wk gestation). Prenatal cannabis use was defined as (1) self-reported use and/or a positive toxicology test, (2) self-reported use, (3) a positive toxicology test, and (4) self-reported use frequency. Cox proportional hazards regression models adjusting for maternal characteristics (sociodemographics, other substance use and substance use disorders, prenatal care initiation, comorbidities) examined associations between prenatal cannabis use and offspring ADHD and DBD diagnosed by age 11 years. Results: The sample of pregnant individuals was 27.2% Asian/Pacific Islander, 5.7% Black, 24.5% Hispanic, and 38.8% non-Hispanic White, with a mean (SD) age of 30.9 (5.2) years; 4.6% screened positive for any cannabis use (0.4% daily, 0.5% weekly, 1.1% monthly or less, 2.7% unknown frequency); 3.92% had a positive toxicology test and 1.8% self-reported use; 7.7% of offspring had ADHD and 6.8% had DBD. Maternal prenatal cannabis use was not associated with ADHD (adjusted hazard ratio [aHR]: 0.84, 95% CI, 0.70-1.01), and there was an inverse association with DBD (aHR: 0.83, 95% CI, 0.71-0.97), which remained when cannabis was defined by toxicology testing but not by self-report. Frequency of use was not associated with outcomes. Conclusion: Maternal prenatal cannabis use was not associated with an increased risk of offspring ADHD or DBD.
The impact of recreational cannabinoid legalization on utilization in a pregnant population

Jacob Torres,Colton Miller,Michael Apostol,Jessica Gross,Jessie R. Maxwell

DOI: https://doi.org/10.3389/fpubh.2024.1278834

IF: 5.2

2024-02-20

Frontiers in Public Health

Abstract:Background: Marijuana potency and utilization both continue to increase across the United States. While the overall prevalence of cannabinoid utilization during pregnancy has been surveyed in various studies, the direct impact of changing governmental policies on pregnancy use is less characterized. Thus, we aimed to investigate how the legalization of recreational cannabinoid products impacted use during pregnancy in the state of New Mexico. Methods: Participants who had a live birth during two study epochs were included: pre-legalization (Epoch 1: 1 January 2019–31 March 2021) and post-legalization (Epoch 2: 1 November 2021–30 November 2022). Participants were further divided into case group [prenatal cannabinoid exposure (PCE)] vs. control (no PCE), with cases being identified by documented self-report or a positive laboratory toxicology test for cannabinoid use during pregnancy. Results: A total of 1,191 maternal/infant dyads were included in Epoch 1, and 378 maternal/infant dyads were included in Epoch 2. In Epoch 1, 788 dyads were controls with 403 cases, while Epoch 2 had 292 controls and 86 cases. Interestingly there was a significant decrease in self-report or positive laboratory toxicology tests in Epoch 2 compared to Epoch 1. Infants born following PCE in both Epoch groups were more commonly born via Cesarean section, had significantly smaller birth weight, length, and head circumference as well as significantly lower Apgar scores at 1 and 5 min. Conclusion: The finding of decreased reported cannabinoid use in the post-legalization group is contradictory to previous studies which have shown increased rates of cannabinoid use after legalization. This could be due to multiple factors including changes in screening practices, the COVID-19 pandemic, and lack of commercialization of THC products. Additional studies are needed to further characterize how changing governmental policies impacts utilization during pregnancy.

public, environmental & occupational health
Antioxidant, Antimicrobial and Phytochemical Investigations of Polar Extracts of Euphorbia resinifera Beg., Roots, Stems and Flowers

H. Farah,Abdellah Ech-chahad,A. Lamiri

2014-12-31

Abstract:The phytochemical screening of roots, stems and flowers of Euphorbia resinifera Beg., revealed the presence of saponins, polyphenols, flavonoids, tannins, terpenoids, coumarins, and cardiac glycosides. Quantitative analysis showed that the methanolic extract of roots is the richest in phenolic compounds with an amount of 131.48 ± 8.5 µg GAE/mg of extract. While the methanol extract of the stems is the richest in flavonoids with an amount of 39.14 ± 0.48 µg QE/mg of extract. The antioxidant activity of polar extracts was studied with the method of DPPHo, the methanol extract of the roots showed a strong antioxidant activity (IC 50 = 10.01 ± 0.17 µg/ml). The amount of plyphenoles was correlated with the presence of phenolic compounds with ( ρ = -0.87, p <0.05). In vitro antimicrobial activity of polar extracts was determined against five bacteria and one yeast strain. The results show that extract possessed antimicrobial activity against S. aureus, B. subtilis, M. luteus , MBCs and MICs were determined for the first two strains. The extract of ethyl acetate of roots showed the highest antimicrobial activity (MIC and MBC = 0.5 mg/ml) against B. subtilis , and (MIC = 0.5 mg/ml and MBC = 1 mg/ml) against S. aureus.
Estimating the effects of prenatal cannabis exposure on birth outcomes

Alyssa Vanderziel,James C Anthony,David Barondess,Jean M Kerver,Omayma Alshaarawy

DOI: https://doi.org/10.1111/ajad.13650

2024-09-05

Abstract:Background and objectives: Prenatal cannabis use prevalence in the United States has increased. Relaxation of state-level cannabis policy may be contributing to the diminished risk perception of using cannabis. The main psychoactive constituent of cannabis, delta-9-tetrahydrocannabinol, crosses the placenta, interacting with functional cannabinoid receptors in the fetus. Here, we assess the association between prenatal cannabis exposure (PCE) and a set of birth outcomes. Methods: Using the Michigan Archive for Research on Child Health, a prospective pregnancy cohort, we linked prenatal survey data with neonatal data from state-archived birth records. Recruitment occurred in 23 clinics across Michigan. Pregnant participants with live birth records between October 2017 and January 2022, after exclusion for missing data on cannabis use, birth outcomes, and covariates, were included in the final analytic sample (n = 584). Analyses involved generalized linear models. Results: An estimated 15% (95% confidence interval [CI]: 12%, 18%) of participants reported using cannabis during pregnancy. Covariate-adjusted models revealed an association between PCE and birth size (ß = -0.3; 95% CI: -0.5, -0.003). Discussion and conclusions: Findings suggest a relationship between PCE and smaller birth size. Clinicians should follow guidelines outlined by the American College of Obstetricians and Gynecologists when counseling pregnant patients on cannabis use. Scientific significance: We detected a significant association between PCE and birth size. Most studies focus only on the extremes of birth size, however, use of z-scores allow for assessment of the sex-specific birth weight-for-gestational age distribution, increasing the accuracy of detecting an effect of cannabis exposure on birth size.
Characteristics of women concordant and discordant for urine drug screens for cannabis exposure and self-reported cannabis use during pregnancy

Ryan Bogdan,Shelby D Leverett,Anna M Constantino-Petit,Nicole Lashley-Simms,David B Liss,Emma C Johnson,Shannon N Lenze,Rachel E Lean,Tara A Smyser,Ebony B Carter,Christopher D Smyser,Cynthia E Rogers,Arpana Agrawal,Shelby D. Leverett,Anna M. Constantino-Petit,David B. Liss,Emma C. Johnson,Shannon N. Lenze,Rachel E. Lean,Tara A. Smyser,Ebony B. Carter,Christopher D. Smyser,Cynthia E. Rogers

DOI: https://doi.org/10.1016/j.ntt.2024.107351

IF: 4.071

2024-04-11

Neurotoxicology and Teratology

Abstract:Background Increasing cannabis use among pregnant people and equivocal evidence linking prenatal cannabis exposure to adverse outcomes in offspring highlights the need to understand its potential impact on pregnancy and child outcomes. Assessing cannabis use during pregnancy remains a major challenge with potential influences of stigma on self-report as well as detection limitations of easily collected biological matrices. Objective This descriptive study examined the concordance between self-reported (SR) cannabis use and urine drug screen (UDS) detection of cannabis exposure during the first trimester of pregnancy and characterized concordant and discordant groups for sociodemographic factors, modes of use, secondhand exposure to cannabis and tobacco, and alcohol use and cotinine positivity. Study design The Cannabis Use During Development and Early Life (CUDDEL) Study is an ongoing longitudinal study that recruits pregnant individuals presenting for obstetric care, who report lifetime cannabis use as well as using ( n = 289) or not using cannabis ( n = 169) during pregnancy. During the first trimester pregnancy visit, SR of cannabis use and a UDS for cannabis, other illicit drugs and nicotine are acquired from eligible participants, of whom 333 as of 05/01/2023 had both. Results Using available CUDDEL Study data on both SR and UDS ( n = 333; age 26.6 ± 4.7; 88.6% Black; 45.4% below federal poverty threshold; 56.5% with paid employment; 89% with high school education; 22% first pregnancy; 12.3 ± 3.6 weeks gestation), we classified pregnant individuals with SR and UDS data into 4 groups based on concordance ( k = 0.49 [95% C.I. 0.40–0.58]) between SR cannabis use and UDS cannabis detection during the first trimester: 1) SR+/UDS+ ( n = 107); 2) SR-/UDS- ( n = 142); 3) SR+/UDS- ( n = 44); 4) SR-/UDS+ ( n = 40). Those who were SR+/UDS- reported less frequent cannabis use and fewer hours under the influence of cannabis during their pregnancy. Those who were SR-/UDS+ were more likely to have joined the study at a lower gestational age with 62.5% reporting cannabis use during their pregnancy prior to being aware that they were pregnant. Of the 40 SR-/UDS+ women, 14 (i.e., 35%) reported past month secondhand exposure, or blunt usage. In the subset of individuals with SR and UDS available at trimester 2 ( N = 160) and 3 ( N = 140), concordant groups were mostly stable and > 50% of those in the discordant groups became concordant by the second trimester. Classifying individuals as exposed or not exposed who were SR+ and/or UDS+ resulted in minor changes in group status based on self-report at screening. Conclusion Overall, there was moderate concordance between SR and UDS for cannabis use/exposure during pregnancy. Instances of SR+/UDS- discordancy may partially be attributable to lower levels of use that are not detected on UDS. SR-/UDS+ discordancy may arise from recent use prior to knowledge of pregnancy, extreme secondhand exposure, deception, and challenges with completing questionnaires. Acquiring both self-report and biological detection of cannabis use/exposure allows for the examination of convergent evidence. Classifying those who are SR+ and/or UDS+ as individuals who used cannabis during their first trimester after being aware of their pregnancy resulted in only a minor change in exposure status; thus, relying on self-report screening, at least in this population and within this sociocultural context likely provides an adequate approximation of cannabis use during pregnancy.

neurosciences,toxicology
Reasons pregnant people use cannabis to self‐treat health conditions during pregnancy: Results from a US population‐based survey

Claudia Zaugg,Mishka Terplan,Kieran Mailman,Sarah C. M. Roberts

DOI: https://doi.org/10.1111/dar.13934

2024-08-24

Drug and Alcohol Review

Abstract:Introduction Little is known about reasons pregnant people self‐treat health conditions and pregnancy‐related symptoms with cannabis. Methods We administered a cross‐sectional survey to 3571 pregnant and recently pregnant people from US population‐based panels. Participants who used cannabis at some point during pregnancy were asked which health conditions or symptoms they used cannabis to treat and reasons they used cannabis for self‐treatment. We explored differences in reasons for self‐treatment by sociodemographics. Results Nine‐hundred forty‐six participants indicated they used cannabis during pregnancy. Fifty‐seven percent (n = 578) of those who used cannabis during pregnancy indicated they used cannabis exclusively for health purposes; 39% (n = 347) indicated they used cannabis for health and recreation. The most common reasons for self‐treatment were believing cannabis was safer and more effective than other medications or treatments. Some participants reported not having health insurance or a health care provider as reasons for self‐treatment. Black and Hispanic people, and people with household income under 25,000–$49,999 to report barriers to other medications or treatments as reasons for self‐treatment. People with high school education were more likely than people with more education to report viewing cannabis as safe and effective for self‐treatment. Discussion and Conclusions Most pregnant people self‐treating health conditions or symptoms with cannabis are doing so because they consider it safer and more effective than other medications or treatments. Some people, particularly people of colour and low‐income people, may also self‐treat because they face barriers to other treatments.

substance abuse
"I don't need my kid to be high": prioritizing harm reduction when using cannabis during pregnancy

Erin E Gould,Siddhi S Ganesh,Rachel Carmen Ceasar

DOI: https://doi.org/10.1186/s12954-024-01046-2

2024-09-09

Abstract:Background: Cannabis is the most common illicit substance used in pregnancy. As use continues to increase, understanding peoples' behaviors surrounding cannabis use during pregnancy is needed to improve maternal and child health outcomes. The aim of this study was to better understand pregnant individuals' perceptions and knowledge of cannabis use and use patterns as well as the social and environmental factors that may influence their use. Methods: We conducted interviews with 19 participants between December 2022 and March 2023. Individuals self-identified as BIPOC (Black, Indigenous, People of Color), were over 21 years of age, spoke English or Spanish, resided in California, and had used cannabis during pregnancy in the last 0-2 years. Using qualitative, constructivist grounded theory methods, we analyzed the contexts that contributed to participants' lived experiences surrounding cannabis use behaviors during pregnancy. Results: Participants reported making conscious decisions to responsibly manage their cannabis use during pregnancy to minimize potential harm to the fetus. Participants prioritized making what they perceived to be safer adjustments to their use of cannabis: (1) changing the amount of cannabis used, (2) changing the types of cannabis products used, and (3) changing sources of cannabis procurement. Discussion: Our findings show that pregnant individuals are seeking information about safe cannabis use beyond medical supervision and are open to altering their cannabis consumption patterns. However, they are unable to find trustworthy and evidence-based harm reduction practices which can be implemented to mitigate harm to their unborn children. A harm reduction approach is needed in the field of maternal cannabis use to promote positive maternal and fetal health outcomes. Conclusions: More data is needed on comprehensive harm reduction approaches to cannabis use during pregnancy. This requires implementation of education on these topics in healthcare settings presented by prenatal care clinicians.
Is legal recreational cannabis associated with cannabis use during pregnancy, beliefs about safety, and perceived community stigma?

Sarah Raifman,M. Antonia Biggs,Corinne Rocca,Sarah CM Roberts

DOI: https://doi.org/10.1016/j.drugalcdep.2023.111079

IF: 4.852

2024-01-05

Drug and Alcohol Dependence

Abstract:Background Among pregnant and recently pregnant people we investigated whether legal recreational cannabis is associated with pregnancy-related cannabis use, safety beliefs, and perceived community stigma. Methods In 2022, we surveyed 3,571 currently and recently pregnant English- or Spanish-speaking adults in 37 states. Primary outcomes included cannabis use during pregnancy and two continuous scale measures of beliefs about safety and perceived community stigma. Using generalized linear models and mixed effects ordinal logistic regression with random effects for state, we assessed associations between legal recreational cannabis and outcomes of interest, controlling for state-level and individual-level covariates and specifying appropriate functional form. Results Those who reported cannabis use during pregnancy were more likely to believe it is safe and to perceive community stigma compared to those who did not report use during pregnancy. Legal recreational cannabis was not associated with cannabis use during pregnancy, continuation or increase in use, frequency of use, or safety beliefs. Legal recreational cannabis was associated with lower perceived community stigma (coefficient: -0.07, 95% CI: -0.13, -0.01), including among those who reported use during (coefficient = -0.22, 95% CI: -0.40, -0.04) and prior to but not during (coefficient = -0.19, 95% CI: -0.37, -0.01) pregnancy. Conclusion Findings do not support concerns that legal recreational cannabis is associated with cannabis use during pregnancy or beliefs about safety. Legal recreational cannabis may be associated with lower community stigma around cannabis use during pregnancy, which could have implications for pregnant people's disclosure of use and care-seeking behavior.

psychiatry,substance abuse
Revaccinationsergebnisse in Berlin und München

A. Groth,K. Arnold

DOI: https://doi.org/10.1007/BF02201626

1928-04-01

Zeitschrift für Medizinische Mikrobiologie und Immunologie

Abstract:
Trends in Smoking and Smoking Cessation During Pregnancy from 1985 to 2014, Racial and Ethnic Disparity Observed from Multiple National Surveys

Hongxia Li,Andrew R. Hansen,Zachary McGalliard,Laura Gover,Fei Yan,Jian Zhang

DOI: https://doi.org/10.1007/s10995-018-2437-x

2018-01-01

Maternal and Child Health Journal

Abstract:Objective Current report assessed the trends in smoking prevalence and the percentage of smoking cessation during pregnancy among women from three major races/ethnicities. Methods Data were collected between 1999 and 2014 from the continuous National Health and Nutrition Examination Survey (NHANES). Smoking habits of women while pregnant with the child sampled by NHANES were assessed retrospectively. A total of 28,090 women who gave live birth between 1985 and 2014 were included. The prevalence ratios (PRs) of smoking and quitting smoking during pregnancy were calculated. The adjusted annual prevalence ratio (aaPR: the ratio associated with a 1-year increase in time) was estimated using logistic regression with the year of birth as a predictor. Results With child’s race/ethnicity, gender, and mother’s age controlled, the aaPR of smoking was 0.95 (95% confidence interval 0.92–0.97) for Hispanics, 0.96 (0.94–0.98) for whites, and 0.98 (0.94–1.00) for blacks. The aaPR of quitting smoking was 1.09 (1.02–1.16) for Hispanics, 1.01 (0.97–1.06) for whites, and 1.03 (0.95–1.12) for blacks. Compared with the counterparts aged 35 years or older, pregnant women younger than 20 years were more likely to smoke among whites [PR 1.56 (1.07–2.29)] but less likely among blacks [PR 0.37 (0.26–0.52)]. Conclusions for Practice Smoking prevalence has been declining continuously for all but at different rates among three major races/ethnicities. The risk profiles of smoking during pregnancy were race/ethnicity specific. Culturally appropriate programs should be developed to further reduce the maternal smoking during pregnancy.
Historical Trends in Cannabis Use among U.S. Adults Aged 19-55, 2013-2021

Megan E Patrick,Yuk C Pang,Yvonne M Terry-McElrath,Brooke J Arterberry,Megan E. Patrick,Yuk C. Pang,Yvonne M. Terry-McElrath,Brooke J. Arterberry

DOI: https://doi.org/10.15288/jsad.23-00169

2024-02-27

Journal of Studies on Alcohol and Drugs

Abstract:OBJECTIVE: The current study used U.S. national data to examine trends in cannabis use from 2013-2021, focusing on changes in cannabis prevalence during young and middle adulthood, and whether trends differed by sociodemographic characteristics.METHOD: Data from 2013-2021 from 21,133 respondents aged 19-30 and 29,898 aged 35-55 in the national Monitoring the Future panel study (followed since they were in 12<sup>th</sup> grade in 1976-2020) were used to model historical trends in cannabis prevalence (any 12-month use, any 30-day use, and near-daily use [20+ occasions in the past 30 days]).RESULTS: Prevalence of 12-month, 30-day, and near-daily cannabis use significantly increased from 2013-2021 for both young and middle adults. Trends for all three behaviors indicated either consistent linear increases or two-slope increases where the slope estimate was larger in more recent years. Historical increases in 12-month and 30-day use were similar for young and middle adulthood; the historical increase in near-daily use among middle adults had some evidence for a possible pandemic-related deviation. Historical trends did not differ by race/ethnicity or college degree. Trends for 12-month and 30-day use differed by sex, with females increasing more than males over time, especially during middle adulthood.CONCLUSIONS: Significant increases in the prevalence of cannabis use have occurred over the past decade for young and middle adults across sociodemographic groups, with some indication that near-daily use increased among middle adults at the onset of the pandemic. Although males continue to have higher prevalence than females, the gap has narrowed with greater increases in cannabis use among women.

substance abuse,psychology
Women's Questions About Perinatal Cannabis Use and Health Care Providers' Responses

Kelly C Young-Wolff,Kathleen Gali,Varada Sarovar,Geoffrey W Rutledge,Judith J Prochaska

DOI: https://doi.org/10.1089/jwh.2019.8112

Abstract:Background: Cannabis use is common among individuals of reproductive age. We examined publicly posted questions about perinatal cannabis use and licensed United States health care provider responses. Materials and Methods: Data were medical questions on perinatal cannabis use posted online from March 2011 to January 2017 on an anonymous digital health platform. Posters were able to "thank" health care providers for their responses and providers could "agree" with other provider responses. We characterized 364 user questions and 596 responses from 277 unique providers and examined endorsement of responses through provider "agrees" and user "thanks." Results: The most frequent questions concerned prenatal cannabis use detection (24.7%), effects on fertility (22.6%), harms of prenatal use to the fetus (21.3%), and risks of baby exposure to cannabis through breast milk (14.4%). Provider sentiment in responses regarding the safety of perinatal cannabis use were coded as 55.6% harmful, 8.8% safe, 8.8% mixed/unsure, and 26.8% safety unaddressed. Half of providers (49.6%) discouraged perinatal cannabis use, 0.5% encouraged use, and 49.9% neither encouraged nor discouraged use. Provider responses received 1,004 provider "agrees" and 583 user "thanks." Provider responses indicating that perinatal cannabis use is unsafe received more provider "agrees" than responses indicating that use is safe (B = 0.42, 95% CI 0.02-0.82, p = 0.04). User "thanks" did not differ by provider responses regarding safety or dis/encouragement. Conclusion: The data indicate public interest in cannabis use effects before, during, and after pregnancy. While most health care providers indicated cannabis use during pregnancy and breastfeeding is not safe, many did not address safety or discourage use, suggesting a missed educational opportunity.
Changes in prenatal cannabis‐related diagnosed disorders after the Cannabis Act and the COVID‐19 pandemic in Quebec, Canada

José Ignacio Nazif‐Munoz,Pablo Martínez,Christophe Huỳnh,Victoria Massamba,Isaora Zefania,Louis Rochette,Helen‐Maria Vasiliadis

DOI: https://doi.org/10.1111/add.16564

2024-06-21

Addiction

Abstract:Background and aims Public health concerns regarding pregnant women's health after the enactment of the Cannabis Act in Canada (CAC) (a law that allowed non‐medical cannabis use), and the potential impact of the COVID‐19 pandemic, call for a contemporary assessment of these two events. Our study measured associations between the CAC, the COVID‐19 pandemic and the monthly prevalence rates of cannabis‐, all drug‐ and alcohol‐related diagnosed disorders among pregnant women in the province of Quebec. Design, setting and participants This was a quasi‐experimental design applying an interrupted time‐series methodology in the province of Quebec, Canada. The participants were pregnant women aged 15–49 years, between January 2010 and July 2022. Measurements Administrative health data from the Québec Integrated Chronic Disease Surveillance System were used to classify pregnant women according to cannabis‐, all drug (excluding cannabis)‐ and alcohol‐related disorders. The CAC (October 2018) and the COVID‐19 pandemic (April 2020) were evaluated as (1) slope changes and (2) level changes. Cannabis‐, all drug (excluding cannabis)‐ and alcohol‐related disorders were measured by total monthly age‐standardized monthly prevalence rate of each disorder for pregnant women aged 15–49 years. Findings Before the CAC, the prevalence rate of cannabis‐related diagnosed disorders significantly increased each month by 0.5% [95% confidence interval (CI) = 0.3–0.6] in the pregnant population. After the CAC, there were significant increases of 24% (95% CI = 1–53) of cannabis‐related diagnosed disorders. No significant changes were observed for all drug (excluding cannabis)‐ and alcohol‐related diagnosed disorders associated with the CAC. A non‐significant decrease of 20% (95% CI = −38 to 3) was observed during the COVID‐19 pandemic in alcohol‐related disorders. Conclusions The monthly incidence rates of diagnosed cannabis‐related disorders in pregnant women in Quebec increased significantly following the enactment of the Cannabis Act in Canada. Diagnoses of all drug (excluding cannabis)‐ and alcohol‐related disorders remained relatively stable.

psychiatry,substance abuse
Maternal, Fetal and Neonatal Outcomes Related to Recreational Cannabis Use during Pregnancy: Analysis of a Real-World Clinical Data Warehouse between 2010 and 2019

Emilie Bouquet,Pascal Blouin,Marie-Christine Pérault-Pochat,Caroline Carlier-Guérin,Frédéric Millot,Jean-Baptiste Ricco,Joe De Keizer,Stéphanie Pain,Farid Guétarni

DOI: https://doi.org/10.3390/ijerph20176686

2023-08-30

Abstract:Background: Cannabis is the main illicit psychoactive substance used in French childbearing women and very few data are available about adverse events (AEs) related to its use during pregnancy. The aim of this study was to evaluate the association between recreational cannabis use during pregnancy and adverse outcomes from a real-world clinical data warehouse. Methods: Data from the Poitiers University Hospital warehouse were analyzed between 1 January 2010 and 31 December 2019. Logistic regression models were used to evaluate associations between outcomes in three prenatal user groups: cannabis alone ± tobacco (C ± T) (n = 123), tobacco alone (T) (n = 191) and controls (CTRL) (n = 355). Results: Pregnant women in the C ± T group were younger (mean age: 25.5 ± 5.7 years), had lower pre-pregnancy body mass index (22.8 ± 5.5 kg/m2), more psychiatric history (17.5%) and were more likely to benefit from universal free health-care coverage (18.2%) than those in the T and CTRL groups. Cannabis use increases the occurrence of voluntary interruption of pregnancy, at least one AE during pregnancy, at least one neonatal AE, the composite adverse pregnancy outcome over 28, prematurity and small for gestational age. Conclusion: Given the trivialization of recreational cannabis use during pregnancy, there is an urgent need to communicate on AEs of cannabis use during pregnancy.
Association between state‐level medical marijuana legalization and marijuana use during pregnancy: A population‐based study

Mohammad Rifat Haider,Sabrina Karim,Jayani Jayawardhana,Nathan B. Hansen,Zelalem T. Haile

DOI: https://doi.org/10.1111/ajad.13651

2024-10-01

American Journal on Addictions

Abstract:Background and Objectives Despite marijuana's association with adverse pregnancy and birth outcomes, its use during pregnancy increased over the last two decades. During this period, medical marijuana has been legalized in 38 states and the District of Columbia. States with legalized medical marijuana have observed increased marketing of marijuana and related products. This study aims to examine the association between state‐level medical marijuana legalization and marijuana use during pregnancy in the United States. Methods Using the 2015–2021 National Survey on Drug Use and Health, we evaluated the association between marijuana use in the past month among currently pregnant mothers (N = 4338) and legalized medical marijuana in their state of residence. Survey‐weighted descriptive, bivariate, and multivariable logistic regression analyzes were performed. Results About 5.7% of pregnant women reported using marijuana in the past month, and 59.0% lived in a state where medical marijuana was legalized across 2015–2021. Compared to those living in states without marijuana legalization, more pregnant women living in states with marijuana legalization reported using marijuana (4.6% vs. 6.5%). In the multivariable model, pregnant women residing in states with medical marijuana legalization were more likely to use marijuana than residents of states without legalization (adjusted Odds Ratio: 1.56; 95% Confidence Interval: 1.11–2.18). Conclusion and Scientific Significance This is the first known study to find that pregnant women living in states where medical marijuana is legalized are more likely to use marijuana during pregnancy. Pregnant women should be informed of adverse pregnancy and birth outcomes linked to marijuana use during pregnancy.

substance abuse
Prenatal cannabis use disorder and gastroschisis in California, 2007–19

Erin Delker,Rebecca J Baer,Ann E Kelly,Christina Chambers,Gretchen Bandoli

DOI: https://doi.org/10.1093/ije/dyae042

IF: 9.685

2024-02-14

International Journal of Epidemiology

Abstract:Abstract Background Gastroschisis is a congenital anomaly of the abdominal wall with an unknown aetiology. Recent trends in the prevalence of gastroschisis suggest that changing environmental or behavioural factors may contribute. We examined whether prenatal cannabis use disorder was associated with gastroschisis. Methods The Study of Outcomes of Mothers and Infants is a population-based cohort compiled of California birth records that have been linked to Department of Health Care Access and Information hospitalization, emergency department and ambulatory surgery records. We included 2007–19 singleton live births (n = 5 774 656). Cannabis use disorder was measured by diagnosis codes at any visit during pregnancy or at birth. Gastroschisis was measured by diagnosis or surgical repair procedure codes at birth or during the first year of life. Results The prevalence of cannabis use disorder was about 1%. The prevalence of gastroschisis was 0.14% and 0.06% among those with and without cannabis use disorder, respectively. There were positive associations between cannabis use disorder and gastroschisis when using a multivariable model [adjusted risk ratio (aRR) = 1.3, 95% confidence interval (CI) 1.0, 1.7) and a matched sample approach (aRR = 1.5, 95% CI 1.1, 2.1). The association varied by maternal age and was largest among people aged >34 years (aRR = 2.5, 95% CI 1.0, 5.8). Conclusions We confirm findings of a positive association between cannabis exposure and gastroschisis and add that it is strongest when maternal age is greater than 34 years. More investigation into whether the association is causal, and why the association varies by maternal age, is encouraged.

public, environmental & occupational health
A Retrospective Cohort Study of Disparities in Urine Drug Testing During the Perinatal Period in an Urban, Academic Medical Center

Ganetsky, Valerie S.

DOI: https://doi.org/10.1007/s10995-024-03940-4

2024-06-08

Maternal and Child Health Journal

Abstract:The purpose of this study was to evaluate disparities in urine drug testing (UDT) during perinatal care at a single academic medical center. This retrospective cohort study included patients who had a live birth and received prenatal care at our institution between 10/1/2015 and 9/30/2020. The primary outcomes were maternal UDT during pregnancy (UDTPN) and UDT only at delivery (UDTDEL). Secondary outcomes included the number of UDTs (UDTNUM) and the association between a positive UDT test result and race/ethnicity. Mixed model logistic regression and negative binomial regression with clustering based on prenatal care locations were used to control for confounders. Of 6,240 live births, 2,265 (36.3%) and 167 (2.7%) received UDTPN and UDTDEL, respectively. Black (OR 2.09, 95% CI 1.54–2.84) and individuals of Other races (OR 1.64, 95% CI 1.03–2.64) had greater odds of UDTPN compared to non-Hispanic White individuals. Black (beta = 1.12, p < 0.001) and Hispanic individuals (beta = 0.78, p < 0.001) also had a positive relationship with UDTNUM. Compared to individuals with non-Medicaid insurance, those insured by Medicaid had greater odds of UDTPN (OR 1.66, 95% CI 1.11–2.49) and had a positive relationship with UDTNUM (beta = 0.89, p < 0.001). No significant associations were found for UDTDEL and race/ethnicity. Despite receiving more UDT, Black individuals were not more likely to have a positive test result compared to non-Hispanic White individuals (OR 0.95, 95% CI 0.72–1.25). Our findings demonstrate persistent disparities in substance use testing during the perinatal period.

public, environmental & occupational health
The longitudinal assessment of prenatal cannabis use on neonatal outcomes

Leah L. Habersham,Yasmin L. Hurd,Yoko Nomura

DOI: https://doi.org/10.1038/s41372-024-02027-w

2024-06-20

Journal of Perinatology

Abstract:To investigate the association between prenatal cannabis use and perinatal outcomes using longitudinal data from pregnant individuals.

pediatrics,obstetrics & gynecology

Analysis on Equilibrium Point of Expectation Propagation Using Information Geometry

The Associations Between Prenatal Cannabis Use Disorder and Neonatal Outcomes

Intentions to Use Cannabis Postpartum: A Qualitative Study of Pregnant Individuals Who Used Cannabis During Early Pregnancy

Prenatal Cannabis Use and Offspring Attention Deficit Hyperactivity Disorder and Disruptive Behavior Disorders: A Retrospective Cohort Study

The impact of recreational cannabinoid legalization on utilization in a pregnant population

Antioxidant, Antimicrobial and Phytochemical Investigations of Polar Extracts of Euphorbia resinifera Beg., Roots, Stems and Flowers

Estimating the effects of prenatal cannabis exposure on birth outcomes

Characteristics of women concordant and discordant for urine drug screens for cannabis exposure and self-reported cannabis use during pregnancy

Reasons pregnant people use cannabis to self‐treat health conditions during pregnancy: Results from a US population‐based survey

"I don't need my kid to be high": prioritizing harm reduction when using cannabis during pregnancy

Is legal recreational cannabis associated with cannabis use during pregnancy, beliefs about safety, and perceived community stigma?

Revaccinationsergebnisse in Berlin und München

Trends in Smoking and Smoking Cessation During Pregnancy from 1985 to 2014, Racial and Ethnic Disparity Observed from Multiple National Surveys

Historical Trends in Cannabis Use among U.S. Adults Aged 19-55, 2013-2021

Women's Questions About Perinatal Cannabis Use and Health Care Providers' Responses

Changes in prenatal cannabis‐related diagnosed disorders after the Cannabis Act and the COVID‐19 pandemic in Quebec, Canada

Maternal, Fetal and Neonatal Outcomes Related to Recreational Cannabis Use during Pregnancy: Analysis of a Real-World Clinical Data Warehouse between 2010 and 2019

Association between state‐level medical marijuana legalization and marijuana use during pregnancy: A population‐based study

Prenatal cannabis use disorder and gastroschisis in California, 2007–19

A Retrospective Cohort Study of Disparities in Urine Drug Testing During the Perinatal Period in an Urban, Academic Medical Center

The longitudinal assessment of prenatal cannabis use on neonatal outcomes